We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.90
Bid: 9.90
Ask: 10.00
Change: 0.15 (1.54%)
Spread: 0.10 (1.01%)
Open: 9.55
High: 10.00
Low: 9.55
Prev. Close: 9.75
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of share options and Directors' dealings

23 Nov 2016 16:21

RNS Number : 9836P
e-Therapeutics plc
23 November 2016
 

23 November 2016

 

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

 

Grant of share options and Directors' dealings

 

Oxford and Newcastle, UK, 23 November 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that on 23 November 2016 the Company granted options over a total of 10,310,000 ordinary shares of 0.1p each to certain executive directors and other employees (the "Optionholders"). The Optionholders are entitled to exercise their options in three tranches (as set out below) on or after the date specified below, if, at the time of exercise, the prevailing market price of the Company's ordinary shares is not less than the price set out below (the "Exercise Price"). Optionholders will be required to pay the Exercise Price to exercise their options.

Number of shares under option Exercise Price Exercise Date

3,436,666 16.76p 23 November 2018

3,436,667 20.95p 23 November 2018

3,436,667 25.14p 23 November 2019

Details of the individual options granted to executive directors are set out below:

Director Number of shares under option

Steve Medlicott 2,000,000

Sean Nicolson 750,000

The options referred to above are otherwise subject to the Rules of the Company's 2013 Performance Share Plan. 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Steve Medlicott

2

Reason for notification

a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

e-Therapeutics plc

b.

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of 0.1p each 

ISIN: GB00B2823H99

b.

Nature of the transaction

Grant of options to subscribe for ordinary shares

c.

Price(s) and volume(s)

 

 

 

 

 

 

Exercise price(s)

Volume(s)

 

£0.1676

666,666

 

 

£0.2095

666,667

 

 

£0.2514

666,667

 

 

d.

Aggregated information- Aggregated Volume

- Price

 

Volume: 2,000,000 options over ordinary shares

Price: N/A

e.

Date of the transaction

23 November 2016

f.

Place of the transaction

London Stock Exchange

         

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Sean Nicolson

2

Reason for notification

a.

Position/Status

Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

e-Therapeutics plc

b.

LEI

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of 0.1p each 

ISIN: GB00B2823H99

b.

Nature of the transaction

Grant of options to subscribe for ordinary shares

c.

Price(s) and volume(s)

 

 

Exercise Price(s)

Volume(s)

 

£0.1676

250,000

 

 

£0.2095

250,000

 

 

£0.2514

250,000

 

 

d.

Aggregated information- Aggregated Volume

- Price

 

Volume: 750,000

Price: N/A

e.

Date of the transaction

23 November 2016

f.

Place of the transaction

London Stock Exchange

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFLRLTLVFIR
Date   Source Headline
15th Mar 201110:35 amRNSHolding(s) in Company
14th Mar 201112:00 pmRNSDirector/PDMR Shareholding
10th Mar 201111:07 amRNSRe-statement of Directors' Interests
10th Mar 201110:20 amRNSHolding(s) in Company
8th Mar 20116:11 pmRNSHolding(s) in Company
8th Mar 20116:01 pmRNSHolding(s) in Company
7th Mar 20118:22 amRNSCompletion of the Placings
4th Mar 20119:13 amRNSDirector/PDMR Shareholding
3rd Mar 20112:08 pmRNSResult of General Meeting
2nd Mar 20119:28 amRNSDirector/PDMR Shareholding
15th Feb 20117:30 amRNSIssue of Equity
3rd Feb 201112:09 pmRNSIssue of Equity
6th Dec 20107:00 amRNSDirectorate Change
29th Oct 20107:00 amRNSe-Therapeutics plc Interim Results
22nd Sep 20107:00 amRNSComprehensive Set of Patents Granted in US
8th Sep 201010:24 amRNSAGM Statement
30th Jul 20108:00 amRNSAnnual Financial Report
29th Jul 201010:23 amRNSAdditional Listing
2nd Jul 20108:00 amRNSDirectors' Interests
29th Jun 20107:00 amRNSFinal Results
25th May 20107:30 amRNSChange of Adviser
29th Apr 20109:02 amRNSIssue of Equity
29th Apr 20107:00 amRNSPre-close operational update and notice of Results
10th Mar 20104:01 pmRNSDirector's interest
2nd Mar 20109:30 amRNSDirector's shareholdings
15th Feb 20107:00 amRNSContract for iGCP trials with Infinitus
11th Nov 20095:46 pmRNSHolding(s) in Company
2nd Nov 200912:00 pmRNSPlacing
30th Oct 20097:00 amRNSInterim results
2nd Sep 200910:05 amRNSResult of AGM
11th Aug 20097:00 amRNSNotice of AGM
27th Jul 20097:42 amRNSPreliminary Results
14th Jul 20097:00 amRNSNotice of Results
25th Jun 20091:00 pmRNSChange of Adviser
17th Jun 20094:05 pmRNSDirector/PDMR Shareholding
9th Jun 200911:36 amRNSDirector Declaration
16th Mar 20094:34 pmRNSResult of General Meeting
11th Mar 20092:19 pmRNSDirector/PDMR Shareholding
25th Feb 20093:00 pmRNSNotice of General Meeting
25th Feb 20097:00 amRNSConditional Investment & Notice of General Meeting
24th Feb 20097:00 amRNSRevenue share agreement with Khandelwal
26th Jan 20097:00 amRNSStrategic Partnership
14th Jan 20097:00 amRNSPositive Phase IIa results for antidepressant
12th Jan 20091:23 pmRNSUS patent granted
12th Nov 20085:04 pmRNSShare Option Award
11th Nov 20083:02 pmRNSGrant of patents
31st Oct 20087:00 amRNSDirector's Shareholding
10th Oct 200812:30 pmRNSPositive PhaseIIa trial of oral asthma drug
8th Oct 20087:00 amRNSInterim Results
15th Sep 20087:00 amRNSe-Therapeutics partners with KeyGen Biotechnology

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.